On December 24, 2008 the US Food & Drug Administration granted tentative approval to Accord Healthcare’s bicalutamide.

Accord is a subsidiary of Intas Pharmaceuticals, Ltd., an Indian company. Accord’s function is licensing and marketing.

Dr. Gleason died December 28, 2008 at the age of 88.

Here is a link to the obituary:

http://www.startribune.com/obituaries/3 … iaec8O7EyU

or

http://tinyurl.com/9g5o2o

The stature of this pioneer is simply incalculable.

Rest in Peace.

Steve

Recent stories on bisphosphonate side effects might be signaling the advent of a new, superior drug, but will Halozyme’s rHuPH20 enzyme solve the problem of jaw necrosis?

Drug development companies operate within the overall consumer culture. We all want better drugs, better everything. Generic Fosamax (alendronate) now costs just $4 at Wal-Mart, Kroger and other retail pharmacies. What might make right now a better than usual time to get word out to the masses that Fosamax carries some dreadful, if quite rare, risks?